Tamoxifen retinopathy: a case report.

Area of Science:

• Ophthalmology
• Oncology
• Medical Imaging

Background:

• Tamoxifen is a widely used medication for breast cancer treatment.
• Tamoxifen retinopathy is a potential ocular side effect that can lead to visual impairment.
• Early identification and monitoring are essential for managing tamoxifen-induced ocular toxicity.

Purpose of the Study:

• To present a case of tamoxifen retinopathy in a 57-year-old woman.
• To illustrate the diagnostic findings associated with tamoxifen retinopathy.

Main Methods:

• Observational case study.
• Review of patient history and clinical examination.
• Spectral-domain Optical Coherence Tomography (SD-OCT) and fluorescein angiography (FA).
• Electro-oculogram (EOG) to assess retinal pigment epithelium function.

Main Results:

• The patient experienced profound visual impairment in both eyes.
• SD-OCT revealed photoreceptor damage (ellipsoid and interdigitation zones) and macular thinning.
• EOG indicated compromised retinal pigment epithelium function with a reduced Arden ratio.

Conclusions:

• Tamoxifen retinopathy can be diagnosed using SD-OCT and EOG.
• The condition is irreversible, emphasizing the need for regular ophthalmic monitoring.
• Ophthalmic consultations, including SD-OCT and EOG, are recommended before and during tamoxifen therapy to detect and prevent further retinal damage.